Bill Text: MI HB5033 | 2013-2014 | 97th Legislature | Introduced

---

Bill Title: Mental health; other; written summary listing side effects of psychotrophic drugs; require distribution of by prescriber or licensed health professional. Amends sec. 719 of 1974 PA 258 (MCL 330.1719).

Spectrum: Partisan Bill (Democrat 6-0)

Status: (Introduced - Dead) 2013-10-02 - Printed Bill Filed 10/02/2013 [HB5033 Detail]

Download: Michigan-2013-HB5033-Introduced.html

---

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HOUSE BILL No. 5033

 

October 1, 2013, Introduced by Reps. Darany, Cavanagh, Santana, Lipton, Roberts and Dillon and referred to the Committee on Health Policy.

 

     A bill to amend 1974 PA 258, entitled

 

"Mental health code,"

 

by amending section 719 (MCL 330.1719), as amended by 1996 PA 588.

 

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

 

     Sec. 719. (1) Before Except as provided in subsection (2),

 

before initiating a course of psychotropic drug treatment for a

 

recipient, the prescriber or a licensed health professional acting

 

under the delegated authority of the prescriber shall do both of

 

the following:

 

     (a) Explain the specific risks, the potential benefits, and

 

the most common adverse effects that have been associated with that

 

drug.

 

     (b) Provide the individual with a written summary of the

 

potential benefits and the most common adverse effects associated

 

with that drug.

 

     (2) Before initiating a course of psychotropic drug treatment

 

for a minor recipient, the prescriber or a licensed health

 

professional acting under the delegated authority of the prescriber

 

shall do all of the following:

 

     (a) Explain to the parent or guardian and the minor recipient

 

the specific risks, the potential benefits, and the most common

 

adverse effects that have been associated with that drug when used

 

on minors.

 

     (b) Provide the parent or guardian and the minor recipient

 

with a written summary of the potential benefits and the most

 

common adverse effects associated with that drug when used on

 

minors.

 

     (c) If the drug has not been tested or approved by the United

 

States food and drug administration for use on minors who are the

 

same age range as the minor recipient, provide that information in

 

a written statement to the parent or guardian and the minor

 

recipient.